High expression of miR‑21 is not a predictor of poor prognosis in all patients with hepatocellular carcinoma
- Peng Sheng Yi
- Jian Shui Li
Affiliations: Department of Hepatobiliary and Pancreatic Disease, Institute of General Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China
- Published online on: April 3, 2018 https://doi.org/10.3892/mco.2018.1603
Copyright: © Yi
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
MicroRNA (miR)‑21 has been identified as a novel biomarker of hepatocellular carcinoma (HCC). However, the prognostic value of miR‑21 expression in HCC remains controversial. The aim of the present study was to investigate the value of high expression of miR‑21 in predicting the prognosis of HCC. Following a search through the PubMed, Science Citation Index, EMBASE and CNKI databases, a total of 9 studies investigating the expression of miR‑21 in HCC and the association between high expression of miR‑21 and prognosis of HCC were identified. It was observed that high expression of miR‑21 was not associated with poor overall survival of all patients with HCC (P=0.52). However, high expression of miR‑21 was found to be correlated with poor prognosis of HCC patients undergoing curative resection (hazard ratio = 2.36; P<0.01). It was also demonstrated that high expression of miR‑21 was correlated with tumor size >5 cm [odds ratio (OR)=1.53; P=0.04], venous invasion (OR=4.86; P=0.01), TNM stage (OR=3.44; P<0.01) and liver cirrhosis (OR=2.12; P=0.03). It was concluded that miR‑21 cannot be considered as a factor complementary to α‑fetoprotein, microvascular invasion and advanced tumor stage in predicting the prognosis of all HCC patients. Higher expression of miR‑21 may be a promising biomarker associated with certain clinicopathological characteristics of HCC, such as tumor size, venous invasion, TNM stage and liver cirrhosis.